Cymbalta Finds Divergent FDA, European Standards For Fibromyalgia Approval

The stance of U.S and European regulators on fibromyalgia drug development is diverging, as Lilly has discovered in pursuing a fibromyalgia claim for Cymbalta (duloxetine).